The Hedgehog receptor patched functions in multidrug transport and chemotherapy resistance

Molecular Cancer Research

Volumn 10, Issue 11, 2012, Pages 1496-1508

  Bidet, Michel ^a   Tomico, Amandine ^a   Martin, Patrick ^a   Guizouarn, Hélène ^a   Mollat, Patrick ^b   Mus Veteau, Isabelle ^a  

^a UNIVERSITÉ CÔTE D'AZUR   (France)

^b Galapagos SASU   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPAMINE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PROTEIN PATCHED; TEMOZOLOMIDE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESISTANCE; DRUG ACCUMULATION; DRUG MECHANISM; FIBROBLAST; GENE EXPRESSION; GENE FUNCTION; HEDGEHOG RECEPTOR PATCHED GENE; MULTIDRUG RESISTANCE; ONCOGENE; OOCYTE; PRIORITY JOURNAL; XENOPUS; YEAST CELL;

ACRIFLAVINE; AMINO ACID SEQUENCE; ANIMALS; BIOLOGICAL TRANSPORT; DOXORUBICIN; DRUG RESISTANCE, MULTIPLE; FIBROBLASTS; HEDGEHOG PROTEINS; HUMANS; K562 CELLS; MICE; MODELS, MOLECULAR; NIH 3T3 CELLS; RECEPTORS, CELL SURFACE; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; XENOPUS;

ERINACEIDAE;

EID: 84869203655     PISSN: 15417786     EISSN: 15573125     Source Type: Journal    
DOI: 10.1158/1541-7786.MCR-11-0578     Document Type: Article

References (50)

1. Beachy PA, Karhadkar SS, Berman DM. Tissue repair and stem cell renewal in carcinogenesis. Nature 2004;432:324-31. (Pubitemid 39551660)
2. Traiffort E, Angot E, Ruat M. Sonic Hedgehog signaling in the mammalian brain. J Neurochem 2010;113:576-90.
3. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008;22:2454-72.
4. Scales S, de Sauvage F. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009;30:303-12.
5. Barakat MT, Humke EW, Scott MP. Learning from Jekyll to control Hyde: Hedgehog signaling in development and cancer. Trends Mol Med 2010;16:337-48.
6. Harris LG, Samant RS, Shevde LA. Hedgehog signaling: networking to nurture a promalignant tumor microenvironment. Mol Cancer Res 2011;9:1165-74.
7. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
8. Liu S, Dontu G, Mantle ID, Patel S, Ahn NS, Jackson KW, et al. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res 2006;66:6063-71.
9. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 2007;17:165-72. (Pubitemid 46107823)
10. Zhao C, Chen A, Jamieson CH, Fereshteh M, Abrahamsson A, Blum J, et al. Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemia. Nature 2009;458:776-9.
11. Song Z, Yue W, Wei B, Wang N, Li T, Guan L, et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One 2011;6:e17687.
12. Sims-Mourtada J, Izzo JG, Ajani J, Chao KS. Sonic Hedgehog promotes multiple drug resistance by regulation of drug transport. Oncogene 2007;26:5674-9. (Pubitemid 47267845)
13. Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, et al. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010;29:6314-22.
14. Singh RR, Kunkalla K, Qu C, Schlette E, Neelapu SS, Samaniego F, et al. ABCG2 is a direct transcriptional target of hedgehog signaling and involved in stroma-induced drug tolerance in diffuse large B-cell lymphoma. Oncogene 2011;30:4874-86.
15. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58. (Pubitemid 37328807)
16. Zhang Y, Laterra J, Pomper MG. Hedgehog pathway inhibitor HhAn-tag691 is a potent inhibitor of ABCG2/BCRP and ABCB1/Pgp. Neoplasia 2009;11:96-101.
17. Bidet M, Joubert O, Lacombe B, Ciantar M, Nehmé R, Mollat P, et al. The hedgehog receptor patched is involved in cholesterol transport. PLoS One 2011;6:e23834.
18. Davies JP, Levy B, Ioannou YA. Evidence for a Niemann-pick C (NPC) gene family: identification and characterization of NPC1L1. Genomics 2000;65:137-45. (Pubitemid 30314421)
19. Scott C, Ioannou Y. The NPC1 protein: structure implies function. Biochim Biophys Acta 2004;1685:8-13.
20. Joubert O, Nehmé R, Fleury D, De Rivoyre M, BidetM, Polidori A, et al. Functional studies of membrane-bound and purified human Hedgehog receptor Patched expressed in yeast. Biochim Biophys Acta 2009;1788:1813-21.
21. Martial S, Guizouarn H, Gabillat N, Pellissier B, Borgese F. Consequences of point mutations in trout anion exchanger 1 (tAE1) transmembrane domains: evidence that tAE1 can behave as a chloride channel. J Cell Physiol 2006;207:829-35. (Pubitemid 43668248)
22. Shen F, Chu S, Bence AK, Bailey B, Xue X, Erickson PA, et al. Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells. J Pharmacol Exp Ther 2008;324:95-102. (Pubitemid 350294163)
23. Paulsen IT, Brown MH, Skurray RA. Proton-dependent multidrug efflux systems. Microbiol Rev 1996;60:575-608. (Pubitemid 26415669)
24. Kolaczkowski M, van der Rest M, Cybularz-Kolaczkowska A, Soumillion JP, Konings WN, Goffeau A. Anticancer drugs, ionophoric peptides, and steroids as substrates of the yeast multidrug transporter Pdr5p. J Biol Chem 1996;271:31543-8. (Pubitemid 26408613)
25. Pisani D, Rivoyre M, Ruel L, Bonino F, Bidet M, Dechesne C, et al. Mouse myodulin, a new potential angiogenic factor, functionally expressed in yeast. Biochem Biophys Res Commun 2005;331:552-6. (Pubitemid 40602673)
26. Husain N, Agbaria RA, Warner IM. Spectroscopic analysis of the binding of doxorubicin to human. alpha.-1 acid glycoprotein. J Phys Chem 1993;97:10857-61.
27. Taipale J, Cooper M, Maiti T, Beachy P. Patched acts catalytically to suppress the activity of Smoothened. Nature 2002;418:892-7. (Pubitemid 34966310)
28. Rohatgi R, Milenkovic L, Scott MP. Patched1 regulates hedgehog signaling at the primary cilium. Science 2007;317:372-6. (Pubitemid 47106377)
29. Rohatgi R, Milenkovic L, Corcoran R, Scott M. Hedgehog signal transduction by Smoothened: pharmacologic evidence for a 2-step activation process. Proc Natl Acad Sci U S A 2009;106:3196-201.
30. Varjosalo M, Li SP, Taipale J. Divergence of hedgehog signal transduction mechanism between Drosophila and mammals. Dev Cell 2006;10:177-86. (Pubitemid 43174951)
31. Fuse N, Maiti T, Wang B, Porter JA, Hall TM, Leahy DJ, et al. Sonic hedgehog protein signals not as a hydrolytic enzyme but as an apparent ligand for patched. Proc Natl Acad Sci U S A 1999;96:10992-9. (Pubitemid 29487317)
32. Taipale J, Chen J, Cooper M, Wang B, Mann R, Milenkovic L, et al. Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine. Nature 2000;406:1005-9.
33. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD.MDA-MB-435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007;104:13-9. (Pubitemid 46976633)
34. Mukherjee S, Frolova N, Sadlonova A, Novak Z, Steg A, Page GP, et al. Hedgehog signaling and response to cyclopamine differ in epithelial and stromal cells in benign breast and breast cancer. Cancer Biol Ther 2006;5:674-83. (Pubitemid 44024723)
35. Detmer K, Walker AN, Jenkins TM, Steele TA, Dannawi H. Erythroid differentiation in vitro is blocked by cyclopamine, an inhibitor of hedgehog signaling. Blood Cells Mol Dis 2000;26:360-72.
36. Martirosyan A, Clendening JW, Goard CA, Penn LZ. Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 2010;10:103.
37. Zhu AJ, Zheng L, Suyama K, Scott MP. Altered localization of Drosophila smoothened protein activates Hedgehog signal transduction. Genes Dev 2003;17:1240-52. (Pubitemid 36583167)
38. Denef N, Neubüser D, Perez L, Cohen SM. Hedgehog induces opposite changes in turnover and subcellular localization of patched and smoothened. Cell 2000;102:521-31.
39. Incardona J, Gruenberg J, Roelink H. Sonic hedgehog induces the segregation of patched and smoothened in endosomes. Curr Biol 2002;12:983-95. (Pubitemid 34703328)
40. Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS, et al. The hedgehog pathway transcription factor GLI1 promotes malignant behavior of cancer cells by up-regulating osteopontin. J Biol Chem 2009;284:22888-97.
41. Guan L, Nakae T. Identification of essential charged residues in transmembrane segments of the multidrug transporter MexB of Pseudomonas aeruginosa. J Bacteriol 2001;183:1734-9. (Pubitemid 32172317)
42. Davies JP, Chen FW, Ioannou YA. Transmembrane molecular pump activity of Niemann-Pick C1 protein. Science 2000;290:2295-8. (Pubitemid 32041568)
43. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res 2006;99:1031-43. (Pubitemid 44729927)
44. Wong WW, Dimitroulakos J, Minden MD, Penn LZ. HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 2002;16:508-19. (Pubitemid 34460459)
45. Follet J, Corcos L, Baffet G, Ezan F, Morel F, Simon B, et al. The association of statins and taxanes: an efficient combination trigger of cancer cell apoptosis. Br J Cancer 2012;106:685-92.
46. Schmidmaier R, Baumann P, Bumeder I, Meinhardt G, Straka C, Emmerich B. First clinical experience with simvastatin to overcome drug resistance in refractory multiple myeloma. Eur J Haematol 2007;79:240-3. (Pubitemid 47231166)
47. Kornblau SM, Banker DE, Stirewalt D, Shen D, Lemker E, Verstovsek S, et al. Blockade of adaptive defensive changes in cholesterol uptake and synthesis in AML by the addition of pravastatin to idarubicin +high-dose Ara-C: a phase 1 study. Blood 2007;109:2999-3006. (Pubitemid 46482100)
48. Goard CA, Mather RG, Vinepal B, Clendening JW, Martirosyan A, Boutros PC, et al. Differential interactions between statins and Pglycoprotein: implications for exploiting statins as anticancer agents. Int J Cancer 2010;127:2936-48.
49. Goldstein J, Brown M. Regulation of the mevalonate pathway. Nature 1990;343:425-30.
50. Cui D, Xu Q, Wang K, Che X. Gli1 is a potential target for alleviating multidrug resistance of gliomas. J Neurol Sci 2010;288:156-66.